Functional Concept – Page 39

Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy

8 months ago talkbio0Tagged AMD, Attitude, Clinical Trials, Failure (biologic function), File (record), Glycogen storage disease type II, OTLK, Prices, United States Food and Drug Administration

Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing

Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations

8 months ago talkbio0Tagged amgen, Clinical Trials, MariTide, Obesity

Amgen, MariTide, weight loss, obesity treatment, clinical trial results

AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback

8 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, Malignant neoplasm of prostate, Metastatic to, Phase 3 Clinical Trials, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).

Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $825M Global Licensing and Collaboration Agreement for Multiple siRNA Programs

8 months ago talkbio0Tagged Arrowhead, Collaboration Agreement, gene therapy, Global Licensing, Hereditary Diseases, Infrequent, Interferes with, RNA, RNA, Small Interfering

Sarepta Therapeutics, Arrowhead Pharmaceuticals, siRNA programs, Global Licensing and Collaboration Agreement, Rare genetic diseases, Gene therapy, RNA interference

Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial

8 months ago talkbio0Tagged AbbVie, Alector, Alzheimer 's disease, Failure (biologic function), Industry, Phase 2 trial

Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry

Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets

8 months ago talkbio0Tagged Alzheimer 's disease, Clinical Trials, decline, Failure (biologic function), Manihot esculenta

Cassava Sciences, Alzheimer’s disease, clinical trial failure, ReThink-ALZ study, stock decline

FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis

8 months ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio Pharma, Heart Diseases, Prealbumin, Senile cardiac amyloidosis, United States Food and Drug Administration

Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment

Navigating JPM Week 2024: Insights and Opportunities in Biopharma

8 months ago talkbio0Tagged Biopharma, deal-making, Industry, Investments, IPOs, JPM, M&A, Network, regulatory, trends qualifier

JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

8 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

8 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty